Literature DB >> 237936

Identification of glucagon in the gastrointestinal tract.

H Sasaki, B Rubalcava, D Baetens, E Blazquez, C B Srikant, L Orci, R H Unger.   

Abstract

Gel filtration studies on Bio-Gel P-10 columns of a 50-fold purified porcine duodenal extract revealed a main peak of glucagon-like immunoreactivity (GLI) in the 2,900 mol wt zone and a smaller peak in the 3,500 mol wt zone, the same zone as the pancreatic glucagon marker. Like pancreatic glucagon, samples of 3,500 mol wt material gave essentially identical measurements in radioimmunoassays employing the pancreatic glucagon-specific antiserum 30K and the GLI crossreacting antiserum 78J, whereas the 2,900 mol wt peptide gave 60-fold higher readings in the 78J assay. On disk gel electrophoresis, the 3,500 mol wt fraction, like pancreatic glucagon, migrated at pH 8.3, whereas the 2,900 mol wt peptide remained at the origin; at pH 4.7, the 2,900 mol wt peptide migrated while the 3,500 mol wt immunoreactive peptide and glucagon remained at the origin. Isoelectric focusing revealed the 3,500 mol wt moiety to have an isoelectric point (pI) of 6.2, the same as pancreatic glucagon, whereas the 2,900 mol wt peptide had an pI greater than 10. The glycogenolytic activity of the 3,500 mol wt peptide in the perfused rat liver did not differ significantly from glucagon, and its adenylate cyclase stimulating activity in partially purified liver cell membranes was comparable to that of glucagon; the 2,900 mol wt peptide had less than 20% of these activities. In samples of 3,500 mol wt material subjected to isoelectric focusing, adenylate cyclase-stimulating activity was confirmed to fractions containing 30K immunoreactivity with a pI of 6.2. In samples of 2,900 mol wt material subjected to isoelectric focusing, adenylate cyclase-stimulating activity was confined to fractions containing 78J immunoreactivity with an pI greater than 10. Displacement of [125-I]glucagon from the membranes was limited to these two biologically active fractions. However, the affinity of both pancreatic glucagon and the 3,500 mol wt peptide was an order of magnitude greater than of the 2,900 mol wt peptide. Thus, by all of several biologic, physiocochemical, and immunometric techniques, the 3,500 mol wt gut immunoreactive peptide could not be distinguished from pancreatic glucagon, while the 2,900 mol wt peptide was readily differentiated by all these techniques. "True" A-cells, ultrastructurally indistinguishable from pancreatic A-cells but differing from the A-like cells of the lower bowel, were identified in the gastric fundus of dogs. Their distribution corresponded to that of the 3,500 mol wt immunoreactivity resembling pancreatic glucagon, while the distribution of "A-like cells" in the lower small intestine corresponded to that of GLI.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 237936      PMCID: PMC436564          DOI: 10.1172/JCI108062

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

1.  Extractable glucagon of the human pancreas.

Authors:  A J KENNY
Journal:  J Clin Endocrinol Metab       Date:  1955-09       Impact factor: 5.958

2.  Inhibition of insulin secretion by somatostatin.

Authors:  K G Alberti; N J Christensen; S E Christensen; A P Hansen; J Iversen; K Lundbaek; K Seyer-Hansen; H Orskov
Journal:  Lancet       Date:  1973-12-08       Impact factor: 79.321

3.  Action of streptozotocin on insulin and glucagon responses of rat islets.

Authors:  N Katsilambros; Y A Rahman; M Hinz; R Fussgänger; K E Schröder; K Straub; E F Pfeiffer
Journal:  Horm Metab Res       Date:  1970-09       Impact factor: 2.936

4.  Ultrastructural and immunofluorescent investigations on the secretin cell in the dog intestinal mucosa.

Authors:  G Bussolati; C Capella; E Solcia; G Vassallo; P Vezzadini
Journal:  Histochemie       Date:  1971

5.  Glucagon as the portal factor modifying hepatic regeneration.

Authors:  J B Price; K Takeshige; M H Max; A B Voorhees
Journal:  Surgery       Date:  1972-07       Impact factor: 3.982

6.  [Ultrastructure of endocrine cells in the gastrointestinal epithelium].

Authors:  L Orci; W G Forssmann; C Rouiller
Journal:  Verh Anat Ges       Date:  1969

7.  Glucagon: role in the hyperglycemia of diabetes mellitus.

Authors:  R Dobbs; H Sakurai; H Sasaki; G Faloona; I Valverde; D Baetens; L Orci; R Unger
Journal:  Science       Date:  1975-02-14       Impact factor: 47.728

8.  Abnormal secretion of insulin and glucagon by the in vitro perfused pancreas of the genetically diabetic Chinese hamster.

Authors:  B J Frankel; J E Gerich; R Hagura; R E Fanska; G C Gerritsen; G M Grodsky
Journal:  J Clin Invest       Date:  1974-06       Impact factor: 14.808

9.  The effect of experimental insulin deficiency on glucagon secretion.

Authors:  W A Müller; G R Faloona; R H Unger
Journal:  J Clin Invest       Date:  1971-09       Impact factor: 14.808

10.  Improvements in epoxy resin embedding methods.

Authors:  J H LUFT
Journal:  J Biophys Biochem Cytol       Date:  1961-02
View more
  40 in total

1.  The effect of somatostatin on the response of GLI to the intraduodenal administration of glucose, protein, and fat.

Authors:  H Sakurai; R E Dobbs; R H Unger
Journal:  Diabetologia       Date:  1975-10       Impact factor: 10.122

2.  Plasma glucagon immunoreactivity in a totally pancreatectomized patient.

Authors:  M L Villanueva; J A Hedo; J Marco
Journal:  Diabetologia       Date:  1976-12       Impact factor: 10.122

3.  Plasma glucagon in insulinoma.

Authors:  A Ohneda; K Matsuda; K Horigome; S Ishii; A Yanbe; Y Maruhama
Journal:  Acta Diabetol Lat       Date:  1977 Sep-Dec

4.  Vagal stimulation and its role in eliciting gastrin but not glucagon release from the isolated perfused dog stomach.

Authors:  P J Lefebvre; A S Luyckx; A H Brassinne
Journal:  Gut       Date:  1978-03       Impact factor: 23.059

Review 5.  Evolution of the restorative proctocolectomy and its effects on gastrointestinal hormones.

Authors:  Amosy E M'Koma; Paul E Wise; Roberta L Muldoon; David A Schwartz; Mary K Washington; Alan J Herline
Journal:  Int J Colorectal Dis       Date:  2007-06-19       Impact factor: 2.571

6.  Lack of gastrointestinal glucagon response to hypoglycaemia in depancreatized dogs.

Authors:  T Matsuyama; R Tanaka; K Shima; K Nonaka; S Tarui
Journal:  Diabetologia       Date:  1978-12       Impact factor: 10.122

7.  Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin.

Authors:  J E Gerich; M Lorenzi; D M Bier; E Tsalikian; V Schneider; J H Karam; P H Forsham
Journal:  J Clin Invest       Date:  1976-04       Impact factor: 14.808

8.  The serum glucose response to glucagon suppression with somatostatin, insulin or antiglucagon serum in depancreatized rats.

Authors:  J C Dunbar; M F Walsh; P P Foà
Journal:  Diabetologia       Date:  1978-01-14       Impact factor: 10.122

9.  Extrapancreatic glucagon and glucagonlike immunoreactivity in depancreatized dogs. A quantitative assessment of secretion rates and anatomical delineation of sources.

Authors:  W A Muller; L Girardier; J Seydoux; M Berger; A E Renold; M Vranic
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

10.  The role of glucagon deficiency in the Houssay phenomenon of dogs.

Authors:  H Nakabayashi; R E Dobbs; R H Unger
Journal:  J Clin Invest       Date:  1978-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.